D
Dirk Pikaart
Researcher at University of Colorado Colorado Springs
Publications - 3
Citations - 410
Dirk Pikaart is an academic researcher from University of Colorado Colorado Springs. The author has contributed to research in topics: Endometrial cancer & Progression-free survival. The author has an hindex of 3, co-authored 3 publications receiving 193 citations.
Papers
More filters
Journal ArticleDOI
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader,Dana M. Roque,Eric R. Siegel,Natalia Buza,Pei Hui,Osama Abdelghany,Setsuko K. Chambers,Angeles Alvarez Secord,Laura J. Havrilesky,David M. O'Malley,Floor J. Backes,Nicole S. Nevadunsky,Babak Edraki,Dirk Pikaart,William J. Lowery,K. ElSahwi,Paul Celano,Stefania Bellone,Masoud Azodi,Babak Litkouhi,Elena Ratner,Dan-Arin Silasi,Peter E. Schwartz,Alessandro D. Santin +23 more
TL;DR: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival, and no unexpected safety signals emerged.
Journal ArticleDOI
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Amanda N. Fader,Dana M. Roque,Eric R. Siegel,Natalia Buza,Pei Hui,Osama Abdelghany,Setsuko K. Chambers,Angeles Alvarez Secord,Laura J. Havrilesky,David M. O'Malley,Floor J. Backes,Nicole S. Nevadunsky,Babak Edraki,Dirk Pikaart,William J. Lowery,K. ElSahwi,Paul Celano,Stefania Bellone,Masoud Azodi,Babak Litkouhi,Elena Ratner,Dan-Arin Silasi,Peter E. Schwartz,Alessandro D. Santin +23 more
TL;DR: Addition of T to C/P increased PFS and OS in women with advanced/recurrent HER2/Neu-positive USC, with the greatest benefit seen for the treatment of stage III to IV disease.
Journal ArticleDOI
Clinical outcomes of image guided radiation therapy (IGRT) with gold fiducial vaginal cuff markers for high-risk endometrial cancer
TL;DR: Daily image guidance for high-risk endometrial cancer results in a low incidence of acute GI/genitourinary toxicity with uncompromised tumor control at two years and actuarial overall survival is 95%.